Digestive enzyme supplements are marketed aggressively for bloating, gas, indigestion, and general “digestive support” — yet the clinical evidence supporting their use in healthy adults without a diagnosed enzyme deficiency is thin. Genuine enzyme deficiency conditions, by contrast, have robust evidence for targeted enzyme replacement therapy. The gap between what the supplement marketing implies and what the clinical evidence supports is wider for digestive enzymes than for almost any other supplement category, making it essential to distinguish between the specific conditions where enzyme supplementation is genuinely indicated and the broad wellness claims that are not supported by trial data.
This article covers the major categories of digestive enzyme supplements — pancreatic enzyme replacement therapy (PERT), lactase, alpha-galactosidase, and multi-enzyme OTC products — the conditions that create a genuine indication for each, how to evaluate OTC enzyme product quality, and the populations most likely to benefit from versus be misled by enzyme supplementation. The broader landscape of digestive supplements is covered in the overview on supplements for digestive health. The interaction between digestive enzyme function, gut motility, and medications is also relevant to understanding digestive symptoms alongside the information in the article on pain relievers and stomach safety.
How Digestive Enzymes Work: The Normal Process
Digestion depends on enzymatic breakdown of macronutrients at multiple sites in the GI tract. Understanding the normal process clarifies where enzyme supplementation can be meaningful and where it is redundant:
Salivary enzymes: Salivary amylase begins starch hydrolysis in the mouth and continues briefly in the stomach before acid denaturation. Lingual lipase provides a minor contribution to fat digestion. These are rarely the rate-limiting step in digestion in healthy adults.
Gastric enzymes: Pepsinogen is secreted by gastric chief cells and activated by gastric acid to pepsin, which begins protein hydrolysis. Gastric lipase contributes 10–30% of total fat digestion and is notably acid-stable, making it particularly important when pancreatic lipase is deficient.
Pancreatic enzymes: The pancreas secretes the most clinically significant digestive enzymes — lipase, amylase, and a suite of proteases (trypsin, chymotrypsin, elastase, carboxypeptidases). Pancreatic lipase is essential for fat absorption; when it is deficient (exocrine pancreatic insufficiency), fat malabsorption is the dominant clinical problem. Pancreatic secretion is triggered by the release of cholecystokinin (CCK) and secretin from the duodenal mucosa in response to fat and protein arriving from the stomach.
Brush border enzymes: The small intestinal mucosa expresses lactase, sucrase-isomaltase, and maltase-glucoamylase, which complete the hydrolysis of disaccharides to monosaccharides for absorption. Lactase deficiency is the most common brush-border enzyme deficiency and the most relevant for supplement use.
When Enzyme Supplements Are Genuinely Indicated
There are three conditions where enzyme supplementation has robust clinical evidence:
1. Exocrine Pancreatic Insufficiency (EPI): EPI occurs when the pancreas produces insufficient digestive enzymes, typically due to chronic pancreatitis, cystic fibrosis, pancreatic cancer, pancreatic surgery, or severe coeliac disease. The clinical picture is characteristic — steatorrhoea (oily, floating, foul-smelling stools), weight loss, fat-soluble vitamin deficiencies (A, D, E, K), and, in severe cases, protein-energy malnutrition. Prescription pancreatic enzyme replacement therapy (PERT — Creon, Zenpep, Pancreaze) uses porcine-derived pancreatic extract with precisely characterised lipase, amylase, and protease content. The standard starting dose for EPI is 40,000–50,000 lipase units per main meal with dose titration based on symptom response and faecal fat measurement. PERT is a prescription treatment, not an OTC supplement choice.
2. Lactose intolerance: Lactase (Lactaid, Lacteeze) supplements are among the best-evidenced OTC enzyme supplements available. Multiple RCTs demonstrate that lactase supplementation taken with dairy meals significantly reduces lactose intolerance symptoms — bloating, gas, cramping, diarrhoea — in people with confirmed or presumed lactase deficiency. The key dosing consideration is taking lactase at the start of the dairy-containing meal (not before, not after) and using an adequate dose — the FCC (Food Chemical Codex) unit dosing on the label should be proportional to the lactose content of the meal. Low-dose lactase products may not provide sufficient enzyme for meals with significant dairy content.
3. Alpha-galactosidase for legume and cruciferous vegetable digestion: Alpha-galactosidase (Beano and similar products) hydrolyses the oligosaccharides in beans, lentils, and brassica vegetables that the human small intestine cannot digest — these pass to the colon where bacterial fermentation produces gas. Multiple clinical trials confirm that alpha-galactosidase taken at the start of legume-containing meals reduces bloating and flatulence in a significant proportion of people. This is not treating a pathological enzyme deficiency — it is supplementing an enzyme that humans do not produce — but the supplement has genuine functional utility for people who experience significant gas with high-legume or high-brassica diets.
OTC Multi-Enzyme Blends: What the Evidence Actually Shows
The majority of the digestive enzyme supplement market consists of multi-enzyme blends — products combining amylase, protease, lipase, lactase, cellulase, and other enzymes — marketed for bloating, indigestion, and improved nutrient absorption in healthy adults. The clinical evidence for these products in people without a diagnosed enzyme deficiency is sparse and inconsistent:
Why the evidence is weak: For oral enzyme supplements to work, the enzymes must survive gastric acid, arrive in the small intestine in an active form, and be present in sufficient quantity to add meaningful enzymatic capacity beyond what the pancreas is already secreting. In healthy adults, the pancreas has substantial reserve capacity — it can increase enzyme output severalfold in response to meal composition — meaning that adding extra enzymes via a supplement rarely addresses a genuine deficiency. Lipase is particularly vulnerable to acid denaturation at gastric pH below 4; most OTC enzyme supplements are not enteric-coated and therefore expose their lipase to the acid environment of the stomach before reaching the small intestine. Prescription PERT products are specifically enteric-coated microspheres to address this problem, but OTC enzyme blends typically are not.
What might genuinely help: OTC enzyme blends containing lactase may help people with undiagnosed or borderline lactose intolerance. Products containing alpha-galactosidase are useful for legume-related gas. Bromelain (from pineapple) and papain (from papaya) are plant-derived proteases included in many OTC enzyme supplements; some trial evidence suggests they may have modest anti-inflammatory properties and may aid protein digestion in specific contexts, though the evidence base is much smaller than for pancreatic enzymes. For people with borderline exocrine pancreatic function (post-pancreatitis, after pancreatic surgery), OTC enzyme supplements at sub-therapeutic doses are unlikely to adequately replace prescription PERT — but some patients use them alongside or instead of PERT, which their gastroenterologist should be aware of.
If significant bloating, gas, and indigestion are ongoing concerns that have not responded to dietary modification and appropriate use of evidence-based supplements, the appropriate next step is clinical evaluation rather than continued OTC enzyme supplementation. Fat malabsorption from undiagnosed EPI, small intestinal bacterial overgrowth (SIBO), coeliac disease, and lactose intolerance can all present with symptoms that resemble functional bloating, and each has a specific diagnostic test and specific treatment. Considering broader digestive health interventions, including how liver function affects fat digestion and enzyme secretion, is addressed in the article on liver safety and medications.
Age-Related Changes in Digestive Enzyme Function
Digestive enzyme secretion and function change with age in ways that are clinically relevant but often overstated in supplement marketing:
Pancreatic enzyme output decreases modestly with healthy ageing — studies in older adults show 10–30% reductions in lipase and amylase output compared to younger adults. However, the pancreas has substantial reserve capacity, and these modest age-related reductions do not cause clinically significant malabsorption in healthy older adults in the absence of underlying pancreatic disease. Age-related reductions in enzyme output become clinically relevant when combined with other factors: reduced gastric acid output (common in older adults on proton pump inhibitors or with atrophic gastritis), slower gastric emptying, or subclinical pancreatic damage from decades of high-calorie diet or mild recurrent pancreatitis episodes.
Lactase activity decreases with age in people who develop adult-onset lactose intolerance (the majority of the world’s population), but this is a genetically programmed process that begins in childhood in most ethnicities and is not an age-related deterioration unique to older adults. The degree of lactase decline varies significantly by ethnic background — populations with a long history of dairy farming (Northern European, some East African) have much higher rates of lactase persistence into adulthood than East Asian and many other populations. For older adults with new-onset digestive symptoms that include milk or dairy intolerance, lactase supplementation is a reasonable first-line trial before pursuing further investigation.
The practical implication for older adults: if digestive symptoms are significant, the evaluation should focus on excluding the conditions that cause genuine malabsorption (EPI from chronic pancreatitis, coeliac disease, SIBO) rather than defaulting to broad-spectrum enzyme supplementation as a first response. Managing the full picture of digestive health after age 60 is covered in additional detail in the article on anti-diarrheal medications: what to know.
Bromelain, Papain, and Plant-Derived Enzyme Supplements
Two plant-derived proteolytic enzymes — bromelain (from pineapple) and papain (from papaya) — appear in many OTC digestive enzyme blends and are also sold as standalone supplements. Their properties and evidence base differ meaningfully from pancreatic or lactase supplements:
Bromelain: Bromelain is a mixture of proteolytic enzymes extracted from pineapple stem and fruit. Its evidence base in digestion is modest — small trials show it can help with protein digestion and may reduce digestive discomfort after protein-heavy meals in some people. Bromelain has an additional, more well-documented role as a systemic anti-inflammatory agent: at higher doses, a meaningful fraction survives gastric digestion and is absorbed intact, where it exerts demonstrable anti-inflammatory effects on joint and tissue inflammation. This systemic anti-inflammatory use is separate from its digestive function. Bromelain also has platelet aggregation inhibitory activity, which is relevant as a drug interaction — patients on anticoagulants (warfarin, novel oral anticoagulants) or antiplatelet drugs (aspirin, clopidogrel) should consult their clinician before using bromelain supplements at therapeutic doses.
Papain: Papain is a cysteine protease from papaya latex. It is used as a meat tenderiser commercially due to its capacity to break down connective tissue proteins. As a digestive supplement, it provides additional protease activity and may assist protein digestion, particularly for people with reduced gastric acid output (who have less pepsin activity). Evidence for its clinical benefit in digestive symptoms is limited. Papain is not suitable for people with latex allergy — the allergen cross-reactivity between latex and papaya is well-documented.
Serrapeptase: Serrapeptase is a proteolytic enzyme derived from the gut of Serratia bacteria (originally isolated from silkworms). It is marketed for digestive support, inflammation, and sinus symptoms in some markets. The evidence for serrapeptase in digestive conditions specifically is very limited, and its primary evidence base is in anti-inflammatory contexts. Regulatory status varies by country — it is classified as a supplement in some jurisdictions and not approved for digestive claims in others.
Fungal-derived enzyme supplements: Many commercial OTC digestive enzyme blends use fungal-derived enzymes (from Aspergillus species) as their amylase, protease, and lipase sources. These are produced by fermentation and are generally stable across a wider pH range than porcine pancreatic enzymes — fungal lipase, for example, retains more activity at lower gastric pH than porcine lipase, which may make some fungal-enzyme products more likely to deliver active lipase to the small intestine than porcine-extract products without enteric coating. This theoretical advantage has not been consistently validated in comparative clinical trials.
Digestive bitters and herbal formulations: Products containing gentian root, dandelion, ginger, and artichoke extract are marketed as digestive aids that stimulate endogenous enzyme and bile acid secretion. The mechanism — bitter compounds stimulating cephalic-phase digestive secretions via the vagal pathway — is physiologically plausible and has modest trial evidence for improving symptoms of functional dyspepsia and bloating. These are distinct from enzyme supplements in that they aim to stimulate the body’s own secretion rather than replacing enzymes. Artichoke extract specifically has reasonable evidence for reducing dyspepsia symptoms and modest evidence for bile acid secretion stimulation. These herbal digestive aids occupy a different evidence tier from prescription PERT or lactase but are generally well-tolerated and represent a more biologically plausible approach to functional bloating than broad-spectrum enzyme blends for most adults without an enzyme deficiency. For people with persistent upper GI symptoms, the evaluation should also consider whether antibiotic use has affected gut flora — the interaction between antibiotics and digestive symptoms is covered in the article on antibiotics and digestive side effects. Considering the liver’s role in bile acid production — which interacts directly with fat digestion — is covered in the article on liver safety and medications.
- Lactose intolerance symptoms with dairy: Lactase (Lactaid) at meal start — strong evidence
- Gas and bloating after beans/lentils/broccoli: Alpha-galactosidase (Beano) at meal start — good evidence
- Steatorrhoea, weight loss, fat malabsorption: See a clinician — may indicate EPI requiring prescription PERT
- General bloating and indigestion: OTC multi-enzyme blends have limited evidence — consider dietary causes first
- After pancreatic surgery or chronic pancreatitis: Discuss PERT prescription with your gastroenterologist
- Enzymes must be taken at the start of the relevant meal — not before, not after — to be effective
Frequently Asked Questions
For lactase and alpha-galactosidase, daily use with relevant meals is safe and appropriate — they are replacing or supplementing enzymes that are either absent or simply not produced by humans. For prescription PERT, daily use with all meals and snacks is standard practice for EPI management. For broad-spectrum OTC enzyme blends in healthy adults, daily use is unlikely to cause harm, but the ongoing cost is not justified by clinical evidence of benefit in the absence of a specific enzyme deficiency. The body does not become dependent on or reduce its own enzyme production in response to supplemental enzymes.
EPI is diagnosed with a faecal elastase-1 test (a non-invasive stool test) or faecal fat quantification. Clinical indicators that should prompt testing include: chronic diarrhoea with oily or floating stools; unexplained weight loss despite adequate caloric intake; history of chronic pancreatitis, cystic fibrosis, pancreatic cancer, or pancreatic surgery; or fat-soluble vitamin deficiencies (vitamins A, D, E, K) without a clear dietary explanation. EPI is underdiagnosed because its symptoms overlap with IBS and other functional gut disorders, and because many clinicians do not routinely order faecal elastase testing for unexplained diarrhoea. If you have persistent symptoms that fit the profile above, specifically request faecal elastase testing from your clinician.
It depends entirely on the specific intolerance. Lactose intolerance (lactase deficiency) responds well to lactase supplementation — this is an enzyme deficiency with a direct enzymatic solution. Fructose malabsorption does not have an effective enzyme supplement, since the limitation is in the GLUT5 transporter rather than an enzyme deficiency. Coeliac disease is an immune-mediated gluten sensitivity and cannot be treated with any digestive enzyme supplement — despite the marketing of some products as “gluten-digesting enzymes,” there is no evidence these supplements prevent the immune damage from gluten ingestion in coeliac disease. FODMAP intolerances (beyond lactose) involve fermentation rather than enzyme deficiency and are managed with dietary restriction rather than enzyme supplementation.
For lactase and alpha-galactosidase, which are produced via fermentation (fungal sources for most commercial products), efficacy is well-established regardless of source. For pancreatic enzyme replacement in EPI, porcine-derived PERT remains the standard because the lipase, amylase, and protease profile most closely matches the human pancreatic output. Plant-based and fungal enzyme products marketed as alternatives to porcine PERT have not been validated in clinical trials against the standard porcine-derived PERT products for EPI — they are not appropriate substitutes for patients with genuine EPI. For the OTC market (non-prescription use), plant-based and fungal enzyme supplements are acceptable alternatives, with the caveat that the evidence base applies to the specific formulations tested, not to enzyme supplements as a category.
Most commercial OTC enzyme supplements are stable at room temperature in their sealed original packaging. Prescription PERT products (Creon, Zenpep) should be stored below 25°C and away from heat and humidity. Once opened, some products specify a shorter storage period. Enzymes are proteins and are sensitive to heat — storage in hot environments (car glove compartment, windowsill, near cooking appliances) can reduce activity. If a supplement has been exposed to prolonged heat or moisture, its enzyme activity may be reduced even if it is within the labelled shelf life. Follow the specific storage instructions on the product packaging.
Oily, floating, or foul-smelling stools; unintentional weight loss; persistent diarrhoea not responding to dietary changes; or fat-soluble vitamin deficiencies — these symptoms may indicate exocrine pancreatic insufficiency (EPI) or coeliac disease, both of which require proper diagnosis and specific treatment, not OTC enzyme supplementation. Self-treating with enzyme supplements without a diagnosis can delay the correct diagnosis and treatment.
- Domínguez-Muñoz JE. (2011). Pancreatic exocrine insufficiency: diagnosis and treatment. Journal of Gastroenterology and Hepatology, 26(Suppl 2), 12–16.
- Suarez FL, Savaiano DA, Levitt MD. (1995). A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. New England Journal of Medicine, 333(1), 1–4.
- Di Stefano M, Miceli E, Gotti S, et al. (2007). The effect of oral alpha-galactosidase on intestinal gas production and GI symptoms in irritable bowel syndrome. Digestive Diseases and Sciences, 52(1), 78–83.
- NIH ODS. (2024). Digestive enzymes: fact sheet for consumers. National Institutes of Health. Available at: ods.od.nih.gov
- NHS. (2023). Lactose intolerance. National Health Service. Available at: nhs.uk/conditions/lactose-intolerance
- Leeds JS, Oppong K, Sanders DS. (2011). The role of fecal elastase-1 in detecting exocrine pancreatic disease. European Journal of Gastroenterology & Hepatology, 23(6), 468–475.
- Ianiro G, Pecere S, Giorgio V, et al. (2016). Digestive enzyme supplementation in gastrointestinal diseases. Current Drug Metabolism, 17(2), 187–193.
The EPI section made me realise I should have been investigated years ago. For about four years I have had ongoing loose, pale, oily-looking stools that float, accompanied by significant weight loss that my GP attributed to dietary changes and stress. I have had chronic pancreatitis diagnosed three years ago after acute episodes, and yet nobody has ever mentioned exocrine pancreatic insufficiency or offered a faecal elastase test. I have been buying OTC enzyme supplements that clearly state on the packet that they contain pancreatic enzymes, but this article makes clear that OTC supplements are not the same as prescription PERT — they are not enteric-coated and may not be delivering meaningful lipase activity to the small intestine. I will specifically ask my gastroenterologist about a faecal elastase test and proper prescription PERT at my next appointment. The weight loss from fat malabsorption, if that is what is happening, cannot be fixed by the OTC supplements I have been taking.
Your clinical picture — chronic pancreatitis diagnosis, floating oily stools, weight loss — is a textbook presentation of exocrine pancreatic insufficiency, and you are right to pursue proper investigation. The faecal elastase-1 test is non-invasive (a single stool sample) and gives a quantitative measure of pancreatic enzyme output — a result below 200 mcg/g is consistent with EPI, and below 100 mcg/g indicates severe insufficiency. One important note: some centres also use a 72-hour faecal fat collection as the gold standard test, which is more burdensome but more directly measures fat malabsorption. If your faecal elastase is borderline, this may be the next step. Prescription PERT (Creon is the most commonly prescribed in many countries, available in 10,000, 25,000, and 40,000 lipase unit capsules) is taken with every meal and snack, and the dose is titrated upward until stool normalises and weight stabilises. The standard starting dose for adults with chronic pancreatitis is typically 40,000–50,000 lipase units per main meal. Your gastroenterologist may also need to check and supplement fat-soluble vitamins (A, D, E, K) if they have been depleted by prolonged fat malabsorption.
The section on bromelain and anticoagulant interactions caught me completely off guard. I have been taking a high-dose bromelain supplement for joint inflammation for about two months, on the recommendation of a friend, and I have been on warfarin for a prosthetic heart valve for six years. Nobody at the pharmacy mentioned any interaction when I bought the bromelain. I checked my last three INR results and they have been more variable than usual — trending higher — over the same period I have been taking the bromelain. I have stopped taking it and will discuss with my anticoagulation clinic. The point about platelet aggregation inhibition from bromelain, combined with anticoagulant effects from warfarin, seems potentially significant for someone in my situation. This is exactly the kind of drug-supplement interaction information that should be on the packaging or that a pharmacist should ask about, but apparently is not consistently communicated.